CY1112840T1 - Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινης - Google Patents
Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινηςInfo
- Publication number
- CY1112840T1 CY1112840T1 CY20121100381T CY121100381T CY1112840T1 CY 1112840 T1 CY1112840 T1 CY 1112840T1 CY 20121100381 T CY20121100381 T CY 20121100381T CY 121100381 T CY121100381 T CY 121100381T CY 1112840 T1 CY1112840 T1 CY 1112840T1
- Authority
- CY
- Cyprus
- Prior art keywords
- taci
- anosophein
- fusion proteins
- ligand
- soluble
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
Abstract
Μόρια που παρεισφρέουν στην δέσμευση υποδοχέα του παράγοντα νέκρωσης όγκων με τον προσδέτη αυτού, όπως είναι ευδιάλυτος υποδοχέας, έχουν αποδεδειγμένη χρησιμότητα και στην βασική έρευνα και ως θεραπευτικά. Η παρούσα εφεύρεση παρέχει βελτιωμένους ευδιάλυτους υποδοχείς του αλληλεπιδράστη διαμεμβρανικού ενεργοποιητή και τροποποιητή ασβεστίου και προσδέτη κυκλοφιλίνης (ΤΑCΙ).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29334301P | 2001-05-24 | 2001-05-24 | |
EP09168970A EP2116259B1 (en) | 2001-05-24 | 2002-05-20 | TACI-immunoglobulin fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112840T1 true CY1112840T1 (el) | 2016-02-10 |
Family
ID=23128690
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100079T CY1109751T1 (el) | 2001-05-24 | 2010-01-27 | Πρωτεϊνες συντηξης taci-ανοσοσφαιρινης |
CY20121100381T CY1112840T1 (el) | 2001-05-24 | 2012-04-24 | Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινης |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100079T CY1109751T1 (el) | 2001-05-24 | 2010-01-27 | Πρωτεϊνες συντηξης taci-ανοσοσφαιρινης |
Country Status (28)
Country | Link |
---|---|
US (9) | US20030103986A1 (el) |
EP (2) | EP1436003B3 (el) |
JP (2) | JP2004535182A (el) |
KR (3) | KR100976743B1 (el) |
CN (2) | CN1612750B (el) |
AT (2) | ATE542545T1 (el) |
AU (1) | AU2002305646C1 (el) |
BR (1) | BRPI0209933B8 (el) |
CA (1) | CA2448123C (el) |
CY (2) | CY1109751T1 (el) |
DE (1) | DE60234202D1 (el) |
DK (2) | DK1436003T3 (el) |
EA (2) | EA010594B1 (el) |
ES (2) | ES2379977T3 (el) |
HK (2) | HK1076603A1 (el) |
HR (2) | HRP20030948B1 (el) |
IL (2) | IL158920A0 (el) |
ME (1) | MEP21708A (el) |
MX (1) | MXPA03010687A (el) |
NO (1) | NO337295B1 (el) |
NZ (1) | NZ529638A (el) |
PL (2) | PL219013B1 (el) |
PT (2) | PT2116259E (el) |
RS (2) | RS52228B (el) |
SI (2) | SI1436003T1 (el) |
UA (1) | UA82830C2 (el) |
WO (1) | WO2002094852A2 (el) |
ZA (1) | ZA200308984B (el) |
Families Citing this family (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US6969519B2 (en) | 2000-03-10 | 2005-11-29 | Human Genome Sciences, Inc. | Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17) |
ES2609016T3 (es) * | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
WO2002016411A2 (en) | 2000-08-18 | 2002-02-28 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
EP2270040A3 (en) | 2000-08-18 | 2011-07-06 | Human Genome Sciences, Inc. | Binding polypeptides for B lymphocyte stimulator protein (BLyS) |
WO2002094192A2 (en) | 2001-05-24 | 2002-11-28 | Human Genome Sciences, Inc. | Antibodies against tumor necrosis factor delta (april) |
DK1436003T3 (da) * | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
HUP0500992A3 (en) * | 2001-08-03 | 2007-11-28 | Genentech Inc | Tacis and br3 polypeptides and uses thereof |
US7112410B1 (en) | 2001-08-29 | 2006-09-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor TR21 and methods based thereon |
WO2003024991A2 (en) * | 2001-09-21 | 2003-03-27 | Amgen Inc. | Tall-1 receptor molecules and uses thereof |
US20040018573A1 (en) * | 2002-04-18 | 2004-01-29 | Power Scott D | Production of functional antibodies in filamentous fungi |
AU2003267967B2 (en) * | 2002-06-18 | 2008-11-20 | Zymogenetics, Inc. | Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter |
US20050009149A1 (en) * | 2002-10-11 | 2005-01-13 | West James W. | Production of homotrimeric fusion proteins |
JP5020636B2 (ja) | 2003-11-06 | 2012-09-05 | シアトル ジェネティックス, インコーポレイテッド | リガンドに結合体化可能なモノメチルバリン化合物 |
CA2558811A1 (en) | 2004-03-08 | 2005-09-22 | Zymogenetics, Inc. | Dimeric fusion proteins and materials and methods for producing them |
EP2286844A3 (en) | 2004-06-01 | 2012-08-22 | Genentech, Inc. | Antibody-drug conjugates and methods |
EP3489257A1 (en) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
JP5118037B2 (ja) * | 2005-08-09 | 2013-01-16 | ザイモジェネティクス, インコーポレイテッド | Taci融合分子を用いた異常細胞増殖の処置及び予防のための方法 |
JP2009507777A (ja) | 2005-08-09 | 2009-02-26 | ザイモジェネティクス,インコーポレイティド | TACI−Ig融合分子を用いたB細胞性腫瘍の処置方法 |
EP1924286A4 (en) * | 2005-08-12 | 2010-01-13 | Garvan Inst Med Res | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
NZ597082A (en) | 2005-10-13 | 2013-11-29 | Human Genome Sciences Inc | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
JP5261187B2 (ja) | 2005-11-23 | 2013-08-14 | アクセルロン ファーマ, インコーポレイテッド | アクチビン−ActRIIaアンタゴニストおよび骨成長を促進するための使用 |
EP1996616A1 (en) * | 2006-02-10 | 2008-12-03 | Zymogenetics, Inc. | Truncated il-17ra soluble receptor and methods of using in inflammation |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
BRPI0711823A2 (pt) | 2006-05-15 | 2012-01-17 | Ares Trading Sa | métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig |
US20100093076A1 (en) * | 2006-08-25 | 2010-04-15 | Moore Margaret D | Soluble il-27 receptor |
CN101535335B (zh) * | 2006-08-28 | 2013-10-02 | 阿雷斯贸易股份有限公司 | 含Fc-蛋白的纯化方法 |
JP2010501622A (ja) * | 2006-08-28 | 2010-01-21 | アレス トレーディング ソシエテ アノニム | Fc−融合タンパク質の精製法 |
AU2007291282B2 (en) * | 2006-08-28 | 2011-10-20 | Ares Trading S.A. | Process for the purification of Fc-fusion proteins |
WO2008025748A1 (en) | 2006-08-28 | 2008-03-06 | Ares Trading S.A. | Process for the purification of fc-containing proteins |
CA2663580C (en) * | 2006-09-18 | 2015-03-17 | Compugen Ltd | Bioactive peptides and method of using same |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
AU2008208837A1 (en) | 2007-01-26 | 2008-07-31 | Merck Serono S.A. | Purification of Fc-TACT fusion proteins using the oilbody technology |
US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI667038B (zh) | 2007-02-09 | 2019-08-01 | 美商艾瑟勒朗法瑪公司 | 包含ActRIIa-Fc融合蛋白的醫藥組合物;ActRIIa-Fc融合蛋白於治療或預防與癌症相關的骨質流失之用途;ActRIIa-Fc融合蛋白於治療或預防多發性骨髓瘤之用途 |
CA2681917A1 (en) * | 2007-03-27 | 2008-10-02 | Christopher Hovens | Methods and compositions for treating prostate cancer |
DK2139517T3 (da) * | 2007-03-27 | 2013-08-26 | Zymogenetics Inc | Kombination af blys inhibering og mycophenolat-mofetil til behandling af autoimmunsygdomme |
CN101323643B (zh) | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
PT2769729T (pt) | 2007-09-04 | 2019-05-08 | Compugen Ltd | Polipéptidos e polinucleótidos, e utilizações dos mesmos como um alvo de fármacos para produzir fármacos e agentes biológicos |
EP2207562B1 (en) | 2007-09-18 | 2017-05-31 | Acceleron Pharma, Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
AU2008312406B2 (en) * | 2007-10-16 | 2014-03-06 | Ares Trading S.A. | Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease |
WO2009062926A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis |
CA2705357C (en) * | 2007-11-12 | 2018-10-23 | Ares Trading S.A. | Formulations for taci-immunoglobulin fusion proteins |
CA2703545A1 (en) * | 2007-11-12 | 2009-05-22 | Ares Trading S.A. | Taci-immunoglobulin fusion proteins for treatment of optic neuritis |
KR101591316B1 (ko) | 2007-12-07 | 2016-02-05 | 지모제넥틱스, 인코포레이티드 | 항-사람 il-21 단클론성 항체 |
US8575107B2 (en) * | 2008-01-22 | 2013-11-05 | Compugen Ltd. | Clusterin derived peptide |
WO2009132058A2 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
US8003335B2 (en) | 2008-04-30 | 2011-08-23 | Universite Paris-SUD11 | Levels of APRIL in serum and use in diagnostic methods |
WO2009134633A1 (en) * | 2008-05-01 | 2009-11-05 | Zymogenetics, Inc. | Levels of blys/april heterotrimers in serum and use in diagnostic methods |
EP2313105B1 (en) | 2008-06-27 | 2013-07-24 | ZymoGenetics, Inc. | SOLUBLE HYBRID Fc gamma RECEPTORS AND RELATED METHODS |
FI3750552T3 (fi) | 2008-08-14 | 2023-07-25 | Acceleron Pharma Inc | Gdf-loukkuja |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
JP5727226B2 (ja) * | 2008-09-30 | 2015-06-03 | 協和発酵キリン株式会社 | Frizzled1、Frizzled2又はFrizzled7細胞外システインリッチドメインを含む蛋白質を含有する骨疾患治療用医薬組成物 |
CN102300874B (zh) | 2008-12-08 | 2015-08-05 | 卡姆普根有限公司 | Tmem154多肽和多核苷酸及其作为产生药物和生物制品的药物靶标的用途 |
WO2010096394A2 (en) * | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
WO2010114860A1 (en) * | 2009-03-30 | 2010-10-07 | Acceleron Pharma Inc. | Bmp-alk3 antagonists and uses for promoting bone growth |
MX2011013172A (es) | 2009-06-08 | 2012-04-02 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
IN2012DN03025A (el) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
CA2780457A1 (en) | 2009-11-13 | 2011-05-19 | Five Prime Therapeutics, Inc. | Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2 |
CA2781152A1 (en) | 2009-11-17 | 2011-05-26 | Acceleron Pharma Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
US9428586B2 (en) | 2009-12-01 | 2016-08-30 | Compugen Ltd | Heparanase splice variant |
WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
WO2011109280A1 (en) | 2010-03-05 | 2011-09-09 | Lerner Research Institute | Methods and compositions to treat immune-mediated disorders |
US10745467B2 (en) | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
CA2794483C (en) | 2010-03-26 | 2020-07-07 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
US20150231215A1 (en) | 2012-06-22 | 2015-08-20 | Randolph J. Noelle | VISTA Antagonist and Methods of Use |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
CN101851278B (zh) * | 2010-05-26 | 2013-03-13 | 石药集团中奇制药技术(石家庄)有限公司 | B细胞激活因子拮抗剂及其制备方法与用途 |
MX336540B (es) | 2010-06-08 | 2016-01-22 | Genentech Inc | Conjugados y anticuerpos manipulados geneticamente con cisteina. |
WO2011156356A1 (en) | 2010-06-09 | 2011-12-15 | Zymogenetics, Inc. | Dimeric vstm3 fusion proteins and related compositions and methods |
CA2803391C (en) | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
WO2016030888A1 (en) | 2014-08-26 | 2016-03-03 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of autoimmune disorders |
AU2011272941B2 (en) | 2010-06-30 | 2014-05-29 | Compugen Ltd. | C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
ES2719624T3 (es) | 2010-09-23 | 2019-07-11 | Prec Biologics Inc | Peptidomiméticos de cáncer de colon y de páncreas |
US20120258496A1 (en) * | 2010-09-27 | 2012-10-11 | Boehringer Ingelheim International Gmbh | Production of low fucose antibodies in h4-ii-e rat cells |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
EP2643016A2 (en) | 2010-11-23 | 2013-10-02 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of anemia |
US8951972B2 (en) | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
WO2012090150A2 (en) | 2010-12-27 | 2012-07-05 | Compugen Ltd | New cell-penetrating peptides and uses thereof |
CA2824143C (en) | 2011-01-14 | 2018-12-18 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
CN102085367B (zh) * | 2011-01-19 | 2012-08-22 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用 |
EP2697256A1 (en) | 2011-04-15 | 2014-02-19 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
WO2012160448A2 (en) | 2011-05-25 | 2012-11-29 | Innate Pharma, S.A. | Anti-kir antibodies for the treatment of inflammatory disorders |
EP2726503B1 (en) | 2011-06-30 | 2019-09-04 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
CN103987407B (zh) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其偶联物 |
AU2012318247B2 (en) | 2011-11-14 | 2015-12-17 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
WO2013114367A2 (en) | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
CA2877533C (en) | 2012-06-22 | 2022-08-16 | The Trustees Of Dartmouth College | Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
CN105246507B (zh) | 2012-09-07 | 2019-01-25 | 达特茅斯大学理事会 | 用于诊断和治疗癌症的vista调节剂 |
SI2906298T1 (sl) | 2012-10-12 | 2018-12-31 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo |
EP2906297B1 (en) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepine-antibody conjugates |
WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
BR112015008238A2 (pt) | 2012-10-12 | 2017-11-28 | Adc Therapeutics Sarl | conjugados de pirrolbenzodiazepina-anticorpo anti-cd22 |
JP6392764B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa | ピロロベンゾジアゼピン−抗体結合体 |
CA2941485C (en) | 2012-10-12 | 2018-06-12 | Philip Wilson Howard | Pyrrolobenzodiazepines and conjugates thereof |
WO2014057113A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
EP2914277B1 (en) | 2012-11-02 | 2017-09-13 | Celgene Corporation | Activin-actrii antagonists and uses for treating bone and other disorders |
CN103833856B (zh) * | 2012-11-22 | 2017-05-03 | 上海康岱生物医药技术股份有限公司 | 抑制taci‑baff复合物形成的融合蛋白及其制法和用途 |
JP6527466B2 (ja) | 2012-12-21 | 2019-06-05 | メドイミューン・リミテッドMedImmune Limited | 増殖性疾患および自己免疫疾患の治療に使用するための非対称ピロロベンゾジアゼピンニ量体 |
CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
SG11201507214SA (en) | 2013-03-13 | 2015-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
EP2968585B1 (en) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
MX2016001862A (es) | 2013-08-12 | 2016-08-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento. |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
JP6980384B2 (ja) | 2013-12-16 | 2021-12-15 | ジェネンテック, インコーポレイテッド | 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法 |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
EP3082875B1 (en) | 2013-12-16 | 2020-11-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
RS63295B1 (sr) | 2013-12-24 | 2022-06-30 | Janssen Pharmaceutica Nv | Anti-vista antitela i fragmenti |
US11014987B2 (en) | 2013-12-24 | 2021-05-25 | Janssen Pharmaceutics Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
US11123426B2 (en) | 2014-06-11 | 2021-09-21 | The Trustees Of Dartmouth College | Use of vista agonists and antagonists to suppress or enhance humoral immunity |
WO2015192111A1 (en) | 2014-06-13 | 2015-12-17 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック, インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
EP3388449A3 (en) | 2014-09-12 | 2018-10-24 | F. Hoffmann-La Roche AG | Cysteine engineered antibodies and conjugates |
CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2749716T3 (es) | 2014-10-28 | 2020-03-23 | Merck Patent Gmbh | Métodos de despliegue de proteínas que contienen dominios Fc no covalentes sobre la superficie de células y métodos de selección de las mismas |
JP6734271B2 (ja) | 2014-11-03 | 2020-08-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用 |
AU2015352545B2 (en) | 2014-11-25 | 2020-10-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
MD4801C1 (ro) | 2014-12-03 | 2022-10-31 | Celgene Corporation | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice |
MX2017007169A (es) | 2014-12-03 | 2018-05-02 | Genentech Inc | Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos. |
AU2015357463B2 (en) | 2014-12-05 | 2021-10-07 | Immunext, Inc. | Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
CN114805576A (zh) | 2015-06-24 | 2022-07-29 | 詹森药业有限公司 | 抗vista抗体和片段 |
CN107922479A (zh) | 2015-08-07 | 2018-04-17 | 默克专利股份公司 | 用于有效的位点特异性生物缀合的转谷氨酰胺标签 |
DK3328881T3 (da) | 2015-09-08 | 2019-10-07 | Theripion Inc | Apoa-1 fusionspolypeptider og relaterede sammensætninger og fremgangsmåder |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
TWI756204B (zh) | 2016-02-12 | 2022-03-01 | 比利時商楊森製藥公司 | 抗vista抗體及片段、其用途及鑑定其之方法 |
US20170315132A1 (en) | 2016-03-25 | 2017-11-02 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
BR112018071153A2 (pt) | 2016-04-15 | 2019-04-16 | Immunext, Inc. | anticorpos anti-vista humano e uso dos mesmos |
JP2019515671A (ja) | 2016-04-15 | 2019-06-13 | アルダー バイオファーマシューティカルズ、インコーポレイテッド | 抗pacap抗体及びそれらの使用 |
CA3019398A1 (en) | 2016-04-26 | 2017-11-02 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック, インコーポレイテッド | シルベストロール抗体-薬物コンジュゲート及び使用方法 |
EP3494141A4 (en) | 2016-08-03 | 2020-04-08 | Bio-Techne Corporation | IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY |
EP3496763A1 (en) | 2016-08-11 | 2019-06-19 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
WO2018136163A2 (en) | 2016-12-09 | 2018-07-26 | Theripion, Inc. | Tandem apoa-1 fusion polypeptides |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
LT3544636T (lt) | 2017-02-08 | 2021-06-25 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
EP3612234B1 (en) | 2017-04-20 | 2024-03-13 | ADC Therapeutics SA | Combination therapy with an anti-axl antibody-drug conjugate |
CA3060225A1 (en) | 2017-05-09 | 2018-11-15 | Cyano Biotech Gmbh | Modified microcystins and nodularins |
AU2018278678B2 (en) | 2017-05-09 | 2022-02-03 | Cyano Biotech Gmbh | Method for modifying microcystins and nodularins |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
AU2018316532B2 (en) | 2017-08-18 | 2022-11-24 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
SG11202001907QA (en) | 2017-09-20 | 2020-04-29 | Ph Pharma Co Ltd | Thailanstatin analogs |
JP2021512120A (ja) | 2018-02-02 | 2021-05-13 | バイオ−テクネ コーポレーション | Vistaとvsig3との相互作用を調節する化合物ならびにその製造および使用方法 |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
CN113227119A (zh) | 2018-12-10 | 2021-08-06 | 基因泰克公司 | 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽 |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
EP4004044A1 (en) | 2019-07-24 | 2022-06-01 | H. Lundbeck A/S | Anti-mglur5 antibodies and uses thereof |
WO2021128027A1 (zh) * | 2019-12-24 | 2021-07-01 | 荣昌生物制药(烟台)股份有限公司 | TACI-Fc融合蛋白及其用途 |
EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
KR20230018477A (ko) * | 2020-06-02 | 2023-02-07 | 아레스 트레이딩 에스.아. | IgA 신장병증의 치료와 연관된 방법 |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
AU2022223409A1 (en) | 2021-02-19 | 2023-09-21 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
MX2023013114A (es) | 2021-05-07 | 2023-11-17 | Alpine Immune Sciences Inc | Metodos de dosificacion y tratamiento con una proteina inmunomoduladora de fusion taci-fc. |
JP2024518410A (ja) | 2021-05-07 | 2024-05-01 | ビエラ バイオ インコーポレイテッド | 重症筋無力症を治療するための抗cd19抗体の使用 |
CN117916273A (zh) * | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
KR20240014066A (ko) * | 2021-09-30 | 2024-01-31 | 레메젠 코, 리미티드 | Taci-fc 융합 단백질을 사용하여 쇼그렌 증후군을 치료하는 방법 |
CA3236667A1 (en) * | 2022-06-08 | 2023-12-14 | Jianmin Fang | Method for treating myasthenia gravis with taci-fc fusion protein |
WO2024067756A1 (zh) * | 2022-09-30 | 2024-04-04 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗膜性肾病的方法 |
WO2024077018A2 (en) | 2022-10-04 | 2024-04-11 | Alpine Immune Sciences, Inc. | Methods and uses of taci-fc fusion immunomodulatory protein |
WO2024114777A1 (zh) * | 2022-12-02 | 2024-06-06 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗微小病变型肾病的方法 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5738A (en) | 1848-08-29 | Francis kelsey | ||
US846A (en) | 1838-07-17 | Improvement in revolving fire-arms | ||
DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
DE3578435D1 (de) | 1984-12-06 | 1990-08-02 | Labofina Sa | Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden. |
US4751181A (en) | 1984-12-31 | 1988-06-14 | Duke University | Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
US5861151A (en) * | 1991-12-20 | 1999-01-19 | Bristol-Myers Squibb Co | Soluble fusion molecules with binding specificity for cell adhesion molecules |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
ZA932522B (en) * | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
WO1994009137A1 (en) | 1992-10-15 | 1994-04-28 | Genentech, Inc. | Antibodies against type 2 tumor necrosis factor receptor |
US5650550A (en) | 1993-10-01 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant mice having a deficit of functional estrogen receptors |
US5523227A (en) | 1994-06-17 | 1996-06-04 | The Board Of Trustees Of The Leland Stanford Junior Univ. | DNA encoding calcium-signal modulating cyclophilin ligand |
ATE377073T1 (de) | 1994-12-15 | 2007-11-15 | Yeda Res & Dev | Modulatoren der funktion des fas/ap01 rezeptors |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
DE19533447C1 (de) | 1995-09-09 | 1996-12-05 | Bbs Kraftfahrzeugtechnik | Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze |
AU1158297A (en) | 1995-11-09 | 1997-05-29 | Zymogenetics Inc. | Production of gad65 in methylotrophic yeast |
US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
PT897390E (pt) | 1996-03-14 | 2004-03-31 | Human Genome Sciences Inc | Factor delta e epsilon de necrose tumoral humana |
AU718510B2 (en) | 1996-07-17 | 2000-04-13 | Zymogenetics Inc. | Transformation of pichia methanolica |
US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
JP2002514049A (ja) | 1996-07-17 | 2002-05-14 | ザイモジェネティクス,インコーポレイティド | ピヒア・メタノリカの栄養要求性突然変異体の製造 |
KR20050004269A (ko) | 1996-10-25 | 2005-01-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 뉴트로킨 알파 |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) * | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
WO1998048024A1 (en) * | 1997-04-18 | 1998-10-29 | Biogen, Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
CA2292835A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
JP2002504818A (ja) | 1997-06-06 | 2002-02-12 | リジェネロン ファーマシューティカルズ,インコーポレイテッド | リガンドファミリーのntn−2メンバー |
AU9013998A (en) * | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EA005411B1 (ru) | 1997-09-12 | 2005-02-24 | Апотек Р Энд Д Са | Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей |
ATE453712T1 (de) * | 1999-01-07 | 2010-01-15 | Zymogenetics Inc | Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2 |
US20060067933A1 (en) * | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
NZ513284A (en) | 1999-01-25 | 2003-10-31 | Biogen Inc | BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses |
AU4363200A (en) | 1999-04-19 | 2000-11-02 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical desorders |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
NZ517782A (en) | 1999-08-17 | 2004-01-30 | Biogen Inc | A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease |
EP1218411A4 (en) * | 1999-09-20 | 2004-09-01 | Millennium Pharm Inc | SECRETED PROTEINS AND THEIR USES |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
ES2267593T3 (es) | 2000-02-16 | 2007-03-16 | Genentech, Inc. | Anticuerpos anti-april y celulas hibridomas. |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
WO2001081417A2 (en) * | 2000-04-27 | 2001-11-01 | Biogen, Inc. | Use of taci as an anti-tumor agent |
CA2408617A1 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
EP1310554B1 (en) | 2000-08-11 | 2010-05-26 | Kyowa Hakko Kirin Co., Ltd. | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
ES2329012T3 (es) | 2000-11-07 | 2009-11-20 | Zymogenetics, Inc. | Receptor del factor de necrosis tumoral humano. |
AU2002238052A1 (en) * | 2001-02-20 | 2002-09-04 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
DK1436003T3 (da) * | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
CA2705357C (en) | 2007-11-12 | 2018-10-23 | Ares Trading S.A. | Formulations for taci-immunoglobulin fusion proteins |
-
2002
- 2002-05-20 DK DK02734478.7T patent/DK1436003T3/da active
- 2002-05-20 UA UA20031110605A patent/UA82830C2/uk unknown
- 2002-05-20 PT PT09168970T patent/PT2116259E/pt unknown
- 2002-05-20 EP EP02734478A patent/EP1436003B3/en not_active Expired - Lifetime
- 2002-05-20 US US10/152,363 patent/US20030103986A1/en not_active Abandoned
- 2002-05-20 JP JP2002592326A patent/JP2004535182A/ja not_active Withdrawn
- 2002-05-20 NZ NZ529638A patent/NZ529638A/en not_active IP Right Cessation
- 2002-05-20 AT AT09168970T patent/ATE542545T1/de active
- 2002-05-20 BR BR0209933-0 patent/BRPI0209933B8/pt not_active IP Right Cessation
- 2002-05-20 KR KR1020097013141A patent/KR100976743B1/ko active IP Right Grant
- 2002-05-20 EA EA200600894A patent/EA010594B1/ru not_active IP Right Cessation
- 2002-05-20 DE DE60234202T patent/DE60234202D1/de not_active Expired - Lifetime
- 2002-05-20 WO PCT/US2002/015910 patent/WO2002094852A2/en active Application Filing
- 2002-05-20 PL PL366760A patent/PL219013B1/pl not_active IP Right Cessation
- 2002-05-20 ES ES09168970T patent/ES2379977T3/es not_active Expired - Lifetime
- 2002-05-20 CN CN02812698XA patent/CN1612750B/zh not_active Expired - Lifetime
- 2002-05-20 EP EP09168970A patent/EP2116259B1/en not_active Expired - Lifetime
- 2002-05-20 RS YU92503A patent/RS52228B/en unknown
- 2002-05-20 MX MXPA03010687A patent/MXPA03010687A/es active IP Right Grant
- 2002-05-20 CA CA2448123A patent/CA2448123C/en not_active Expired - Lifetime
- 2002-05-20 EA EA200301146A patent/EA007275B1/ru not_active IP Right Cessation
- 2002-05-20 AU AU2002305646A patent/AU2002305646C1/en not_active Expired
- 2002-05-20 ME MEP-217/08A patent/MEP21708A/xx unknown
- 2002-05-20 SI SI200230868T patent/SI1436003T1/sl unknown
- 2002-05-20 RS RS20120253A patent/RS20120253A1/en unknown
- 2002-05-20 ES ES02734478T patent/ES2334772T7/es active Active
- 2002-05-20 KR KR1020107010485A patent/KR101021124B1/ko active IP Right Grant
- 2002-05-20 PL PL403488A patent/PL403488A1/pl not_active Application Discontinuation
- 2002-05-20 IL IL15892002A patent/IL158920A0/xx active IP Right Grant
- 2002-05-20 SI SI200230979T patent/SI2116259T1/sl unknown
- 2002-05-20 CN CN200910146212XA patent/CN101628111B/zh not_active Expired - Lifetime
- 2002-05-20 PT PT02734478T patent/PT1436003E/pt unknown
- 2002-05-20 AT AT02734478T patent/ATE446771T1/de active
- 2002-05-20 DK DK09168970.3T patent/DK2116259T3/da active
- 2002-05-20 KR KR10-2003-7015353A patent/KR20040030628A/ko not_active Application Discontinuation
-
2003
- 2003-11-19 ZA ZA200308984A patent/ZA200308984B/en unknown
- 2003-11-20 HR HRP20030948AA patent/HRP20030948B1/hr not_active IP Right Cessation
- 2003-11-21 NO NO20035173A patent/NO337295B1/no not_active IP Right Cessation
-
2005
- 2005-09-29 HK HK05108608.2A patent/HK1076603A1/xx not_active IP Right Cessation
- 2005-10-03 US US11/242,294 patent/US7501497B2/en not_active Expired - Lifetime
-
2009
- 2009-01-26 US US12/359,801 patent/US7635767B2/en not_active Expired - Lifetime
- 2009-06-22 JP JP2009147774A patent/JP5149245B2/ja not_active Expired - Lifetime
- 2009-10-26 US US12/605,561 patent/US7964711B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,288 patent/US7951919B2/en not_active Expired - Fee Related
- 2009-11-05 US US12/613,039 patent/US7862814B2/en not_active Expired - Fee Related
-
2010
- 2010-01-27 CY CY20101100079T patent/CY1109751T1/el unknown
- 2010-03-19 HK HK10102899.6A patent/HK1137659A1/xx not_active IP Right Cessation
-
2011
- 2011-05-11 US US13/105,182 patent/US8524232B2/en not_active Expired - Lifetime
- 2011-12-29 IL IL217265A patent/IL217265A/en active IP Right Grant
-
2012
- 2012-04-24 CY CY20121100381T patent/CY1112840T1/el unknown
-
2013
- 2013-05-09 HR HRP20130413AA patent/HRP20130413A2/hr not_active Application Discontinuation
- 2013-08-01 US US13/956,499 patent/US8815238B2/en not_active Expired - Lifetime
-
2014
- 2014-07-15 US US14/331,567 patent/US9346878B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112840T1 (el) | Πρωτεϊνες συντηξης ταci-ανοσοσφαιρινης | |
WO2002066516A3 (en) | Antibodies that bind both bcma and taci | |
BR0212256A (pt) | Proteìnas de fusão de transferrina modificadas | |
ATE473011T1 (de) | Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen | |
ATE533784T1 (de) | Lösliche, einzelkettige proteine des t- zellrezeptors | |
DK1328297T3 (da) | Funktionen af en haptoglobin-hæmoglobin receptor og anvendelser heraf | |
IL171733A (en) | Apo2l (trail) receptor binding peptides and uses thereof | |
EA200600477A1 (ru) | Пептиды и соединения, которые связываются с рецептором | |
ATE452650T1 (de) | Transferrin-fusionsproteinbibliotheken |